Live and heat-killed probiotic: Effects on chronic experimental colitis induced by dextran sulfate sodium (DSS) in rats

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 11, 2015, Pages 20072-20078

  Sang, Li Xuan ^a   Chang, Bing ^a   Wang, Bing Yuan ^a   Liu, Wei Xin ^a   Jiang, Min ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Chronic experimental colitis; Dextran sulfate sodium; Probiotic

Indexed keywords

DEXTRAN SULFATE; HEAT KILLED PROBIOTIC AGENT; INTERLEUKIN 23; INTERLEUKIN 6; LIVE PROBIOTIC AGENT; MESALAZINE; MYELOPEROXIDASE; PROBIOTIC AGENT; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM INFANTIS; BIFIDOBACTERIUM LONGUM; COLON LENGTH; CONTROLLED STUDY; DISEASE ACTIVITY INDEX; DISEASE ASSESSMENT; ENTERITIS; ENZYME ACTIVITY; EXPERIMENTAL COLITIS; HISTOLOGICAL SCORE; INTESTINE PARAMETERS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; LACTOBACILLUS PLANTARUM; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; STREPTOCOCCUS THERMOPHILUS; TH17 CELL; WEIGHT REDUCTION; WESTERN BLOTTING;

EID: 84954286813     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Wilson J, Hair C, Knight R, Catto-Smith A, Bell S, Kamm M, Desmond P, McNeil J, Connell Wl. High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. Inflamm Bowel Dis 2010; 16: 1550-1556.
2. Salim SY and Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 362-381.
3. Ammori JB, Zhang WZ, Li JY, Chai BX and Mulholland MW. Effects of ghrelin on neuronal survival in cells derived from dorsal motor nucleus of the vagus. Surgery 2008; 144: 159-167.
4. Mudter J and Neurath MF. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 2007; 13: 1016-1023.
5. Chen Z, Laurence A, Kanno Y, Pacger-Zavisin M, Zhu BM, Tato C, Yoshimura A, Henniqhausen L, O'shea JJ. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Nati Sci U S A 2006; 103: 8137-8142.
6. Soeters PB. Probiotics: did we go wrong, and if so, where? Clin Nutr 2008; 27: 173-178,.
7. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, Jian R, Dore J. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52: 237-242.
8. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-421.
9. Verma R, Verma AK, Ahuja V and Paul J. Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India. J Clin Microbiol 2010; 48: 4279-4282.
10. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN and Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-443.
11. Huynh HQ, deBruyn J, Guan L, Diaz H, Li M, Girgis S, Turner J, Fedorak R, Madsen K. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 2009; 15: 760-768.
12. Liong MT. Safety of probiotics: translocation and infection. Nutr Rev 2008; 66: 192-202.
13. Barman S, Koley H, Ramamurthy T, Chakrabarti MK, Shinoda S, Nair GB, Takeda Y. Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model. Microbiol Immunol 2013; 57: 762-771.
14. Ueno N, Fujiya M, Segawa S, Moriichi K, Tanabe H, Mizukami Y, Kobayashi N, Ito K, Kohgo Y. Heat-killed body of lactobacillus brevis SBC8803 ameliorates intestinal injury in a murine model of colitis by enhancing the intestinal barrier function. Inflamm Bowel Dis 2011; 17: 2235-2250.
15. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, De Simone C, Madsen K. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004; 126: 1358-1373.
16. Kamada N, Inoue N, Hisamatsu T, Okamoto S, Matsuoka K, Sato T, Chinen H, Hong KS, Yamada T, Suzuki Y, Suzuki T, Watanabe N, Tsuchimoto K, Hibi T. Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis 2005; 11: 455-463.
17. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126: 520-528.
18. Raddatz D, Bockemuhl M and Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 2005; 17: 547-557.
19. Hanai H, Iida T, Yamada M, Sato Y, Takeuchi K, Tanaka T, Kondo K, Kikuyama M, Maruyama Y, Iwaoka Y, Nakamura A, Hirayama K, Saniabadi AR, Watanabe F. Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. World J Gastroenterol 2006; 12: 3393-3399.
20. Jones SA, Horiuchi S, Topley N, Yamamoto N and Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001; 15: 43-58.
21. Alonzi T, Newton IP, Bryce PJ, Di Carlo E, Lattanzio G, Tripodi M, Musiani P, Poli V. Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. Cytokine 2004; 26: 45-56.
22. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM and Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179-189.